Dexlansoprazole, a modified release formulation of an enantiomer of lansoprazole, for the treatment of reflux esophagitis.
Takeda Pharmaceutical Co Ltd is developing dexlansoprazole, an oral controlled-release formulation of an enantiomer of lansoprazole, for the treatment of reflux esophagitis. By January 2008, an NDA for gastric acid-related diseases had been filed with the FDA, and the drug was undergoing phase II trials in Japan for gastroesophageal reflux disease.
Fock
Kwong Ming
KM
Changi General Hospital, Department of Medicine, Division of Gastroenterology, 2 Simei Street 3, 529889, Singapore. kwong_ming_fock@cgh.com.sg
Ang
Tiing Leong
TL
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D002626:Chemistry, Pharmaceutical; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D064748:Dexlansoprazole; D004345:Drug Industry; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D006801:Humans; D064747:Lansoprazole; D010330:Patents as Topic; D054328:Proton Pump Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D064748:Dexlansoprazole